This is a multi-center, randomized, double-blind, placebo-controlled Phase 2 study whose
objectives are to evaluate the clinical efficacy and safety of CAN008 plus TMZ during and
after radiation therapy in newly-diagnosed subjects with glioblastoma who have undergone
surgical excision.